> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Recursion Cuts Its Tempus Data Fee To $14.0 Million A Year, But Loses The Right To Walk Away
- URL: https://www.bullished.co/recursion-cuts-its-tempus-data-fee-to-14-0-million-a-year-but-loses-the-right-to-walk-away-d7bf91db/
- Published: 2026-11-02T22:16:07.000Z
- Updated: 2026-11-02T22:16:07.000Z
- Description: The amended deal adds a year and drops the termination option, while Tempus separately pays $12.0 million to license Recursion's RNA model.
- Author: Matteo Parrino
- Tags: SEC Filings, RXRX, Industry: Healthcare

[Recursion Pharmaceuticals](https://www.bullished.co/tag/rxrx/), which uses AI and automated labs to discover drugs, [cut the annual fee](https://www.sec.gov/Archives/edgar/data/0001601830/000160183026000145/rxrx-20260930.htm?ref=bullished.co) on its Tempus oncology-data contract to $14.0 million but gave up its right to terminate the deal for convenience, according to its quarterly report filed Monday. The September amendment also adds a year to the five-year agreement.

## Lower fee, longer lock

The November 2023 agreement originally called for annual fees of $22.0 million, then $32.0 million, then $42.0 million for each of the last two payments, settled in cash or Class A shares. The original deal let the company terminate for convenience after the first three years, the filing says.

Under the amendment, Recursion pays $14.0 million a year across the final three payment dates, the third through fifth anniversaries. At least $4.0 million of each payment must be in cash. The rest can be paid in Class A stock, cash or both, at Recursion's election. The amount of de-identified patient records the company can access also shrinks.

The [prior quarter's 10-Q](https://www.sec.gov/Archives/edgar/data/0001601830/000160183026000098/rxrx-20260630.htm?ref=bullished.co) described annual payments of $22.0 million to $42.0 million, up to $160.0 million in aggregate.

## Tempus pays $12.0 million for an RNA model

In the same month, Recursion licensed its RNA foundation model, called TxFM, to Tempus for use in oncology. The license is non-exclusive and runs two years. Tempus will pay a non-refundable $12.0 million in two $6.0 million installments, the first on signing and the second on the first anniversary. Recursion is recording no revenue on the license, the filing says. Tempus also gives Recursion some pathology records.

Recursion's Tempus record purchases were $5.8 million in the third quarter and $8.9 million for the first nine months, against zero and $49.9 million a year earlier. The company ties the lower nine-month figure to the timing of record purchases.

## Funding the burn

Recursion's net loss was $119.0 million in the third quarter, against $162.3 million a year earlier. Cash stood at $561.5 million at September 30\. The company has no approved products and has funded itself mainly by selling stock.

Through its TD Cowen at-the-market program, Recursion raised $85.5 million net from 23.7 million Class A shares by September 30, leaving $213.3 million available. On October 16 it completed an underwritten offering of 61.5 million Class A shares for net proceeds of approximately $187.2 million. Recursion's market value was $2.4 billion in Monday trading.

The company says in its [earnings release](https://www.sec.gov/Archives/edgar/data/0001601830/000160183026000144/exhibit991-q0326.htm?ref=bullished.co) that its cash runway now extends into 2029 and that it expects 2026 cash operating expense of less than $375 million.

Recursion hosts an earnings webinar at 8:00 a.m. ET on Tuesday, November 3.

### Sources

- [10-Q Filing — Recursion Pharmaceuticals (RXRX)](https://www.sec.gov/Archives/edgar/data/0001601830/000160183026000145/rxrx-20260930.htm?ref=bullished.co) — SEC EDGAR
- [10-Q Filing — Recursion Pharmaceuticals (RXRX), Q2 FY2026 filed 2026-08-05 (comparison basis)](https://www.sec.gov/Archives/edgar/data/0001601830/000160183026000098/rxrx-20260630.htm?ref=bullished.co) — SEC EDGAR
- [8-K Filing — Recursion Pharmaceuticals, filed 2026-11-02 (Items 2.02, 5.02, 7.01, 9.01)](https://www.sec.gov/Archives/edgar/data/0001601830/000160183026000144/rxrx-20261031.htm?ref=bullished.co) — SEC EDGAR
- [Earnings release (8-K Item 2.02, exhibit991-q0326.htm) — Recursion Pharmaceuticals, filed 2026-11-02](https://www.sec.gov/Archives/edgar/data/0001601830/000160183026000144/exhibit991-q0326.htm?ref=bullished.co) — SEC EDGAR
- [Recursion Pharmaceuticals GAAP EPS of -$0.22 misses by $0.01, revenue of $18.55M beats by $3.74M (NASDAQ:RXRX) | Seeking Alpha](https://seekingalpha.com/news/4662959-recursion-pharmaceuticals-gaap-eps-of-0%5F22-misses-by-0%5F01-revenue-of-18%5F55m-beats-by-3%5F74m?ref=bullished.co) — seekingalpha.com
- [Recursion Pharmaceuticals to Report Q3 Earnings: What's in the Cards?](https://finance.yahoo.com/healthcare/articles/recursion-pharmaceuticals-report-q3-earnings-132200875.html?.tsrc=rss&ref=bullished.co) — Yahoo Finance
- [Recursion Pharmaceuticals (RXRX) Stock May Be Fully Priced As REC 4881 Data Nears](https://uk.finance.yahoo.com/news/recursion-pharmaceuticals-rxrx-stock-may-042843082.html?ref=bullished.co) — Yahoo Finance
- [Recursion Pharmaceuticals (RXRX) Declines More Than Market: Some Information for Investors](https://finance.yahoo.com/markets/stocks/articles/recursion-pharmaceuticals-rxrx-declines-more-204503278.html?.tsrc=rss&ref=bullished.co) — Yahoo Finance
- [Earnings To Watch: Recursion Pharmaceuticals Inc (RXRX) Q3 2026 -- GF Value Sees 35% Downside](https://finance.yahoo.com/markets/stocks/articles/earnings-watch-recursion-pharmaceuticals-inc-132635268.html?ref=bullished.co) — Yahoo Finance

### More on Recursion Pharmaceuticals

- [Recursion Cuts Quarterly Loss To $119.0 Million, Sees Cash Lasting Into 2029](https://www.bullished.co/recursion-cuts-quarterly-loss-to-119-0-million-sees-cash-lasting-into-2029-d85dbb77/)
- [Recursion Prices 61.54 Million New Shares At $3.25, Raising $200 Million Gross Before Fees](https://www.bullished.co/recursion-prices-61-54-million-new-shares-at-3-25-raising-200-million-gross-before-fees-08ed7018/)
- [Recursion Prices $200 Million Stock Sale At $3.25 A Share, Says Cash Now Lasts Into 2029](https://www.bullished.co/recursion-prices-200-million-stock-sale-at-3-25-a-share-says-cash-now-lasts-into-2029-00c3be82/)

[All Recursion Pharmaceuticals (RXRX) coverage →](https://www.bullished.co/tag/rxrx/)